Pancreatic Cancer Research

ResearcherChiba UniversityNo recent work listed

Masaru Miyazaki

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0001-9851-2888; OpenAlex author ID A5101617896, A5112156986. Sources: OpenAlex.

Their work

Papers
35 (first author 0, last author 11)
Trials
0
Grants
0
Labs led
1
Collaborators
61
Papers, trials and grants by year

2011: 1 paper · 2012: 1 paper · 2013: 2 papers · 2014: 2 papers · 2015: 4 papers · 2016: 5 papers · 2017: 8 papers · 2018: 4 papers · 2019: 3 papers · 2020: 1 paper · 2021: 2 papers · 2022: 2 papers

Papers 35

  1. [Liver, Pancreas, Biliary Tract Cancer The Current Status and Future Perspective of Therapies for Advanced Biliary-Pancreatic Cancer]. Co-author PMID 36281594↗
  2. [Ⅰ. Recent Trends in Chemotherapy followed by Surgery for Patients with Locally Advanced Biliary-Pancreatic Cancer]. Co-author PMID 36281595↗
  3. Complement factor B regulates cellular senescence and is associated with poor prognosis in pancreatic cancer. Co-author DOI 10.1007/s13402-021-00614-z↗
  4. [Ⅲ.Surgical Treatment for Recurrence of Pancreatic Cancer]. Co-author PMID 34657053↗
  5. [Ⅱ.Carbon Ion Radiation Therapy as Perioperative Treatment for Pancreatic Cancer]. Co-author PMID 33130735↗
  6. Is hepatic artery coil embolization useful in distal pancreatectomy with en bloc celiac axis resection for locally advanced pancreatic cancer? Co-author DOI 10.1186/s12957-019-1667-8↗
  7. [Postoperative Recurrence of Pancreatic Cancer Successfully Treated with the Gemcitabine plus Oxaliplatin Regimen Resulting in Long-Term Survival-ACase Report]. Last author PMID 30765668↗
  8. [Liver, Pancreas, Biliary Tract Cancer Pre-Operative Down-Sizing(Staging) Chemotherapy for Unresectable Advanced Hepato-Biliary-Pancreatic Cancer Followed by C… Co-author PMID 31631128↗
  9. Expression of annexin II and stromal tenascin C promotes epithelial to mesenchymal transition and correlates with distant metastasis in pancreatic cancer. Co-author DOI 10.3892/ijmm.2018.3652↗
  10. Conversion surgery with gemcitabine plus nab-paclitaxel for locally advanced unresectable pancreatic cancer: A case report. Co-author DOI 10.3892/mco.2018.1688↗
  11. [Pancreas Bed Recurrence Resection Combined with Celiac and Common Hepatic Arterial Resection after Distal Pancreatectomy for Pancreatic Cancer]. Last author PMID 29362327↗
  12. [Liver, Pancreas, Biliary Tract Cancer Current Issues of Surgical Margin, R0 and R1, in Surgical Resection for Hepatobiliary Pancreatic Cancer]. Co-author PMID 30382035↗
  13. Grainyhead-like 2 (GRHL2) regulates epithelial plasticity in pancreatic cancer progression. Co-author DOI 10.1002/cam4.1212↗
  14. Combined hepatic arterial resection in pancreatic resections for locally advanced pancreatic cancer. Co-author DOI 10.1007/s00423-017-1578-5↗
  15. Duffy antigen receptor for chemokines (DARC) expressing in cancer cells inhibits tumor progression by suppressing CXCR2 signaling in human pancreatic ductal ad… Co-author DOI 10.1016/j.cyto.2017.02.007↗
  16. Sex Determining Region Y Box 9 Induces Chemoresistance in Pancreatic Cancer Cells by Induction of Putative Cancer Stem Cell Characteristics and Its High Expres… Last author DOI 10.1097/mpa.0000000000000945↗
  17. Immune-complex level of cofilin-1 in sera is associated with cancer progression and poor prognosis in pancreatic cancer. Co-author DOI 10.1111/cas.13181↗
  18. Metadherin promotes metastasis by supporting putative cancer stem cell properties and epithelial plasticity in pancreatic cancer. Co-author DOI 10.18632/oncotarget.19802↗
  19. [Liver, Pancreas, Biliary Tract New Therapeutic Strategies for Advanced Pancreatic Cancer]. Co-author PMID 29066675↗
  20. [IV. Distal Pancreatectomy with Celiac Axis Resection(DP-CAR)for Locally Advanced Pancreatic Cancer with Celiac Artery Invasion]. Co-author PMID 29066679↗
  21. Identification of a novel serum biomarker for pancreatic cancer, C4b-binding protein α-chain (C4BPA) by quantitative proteomic analysis using tandem mass tags. Co-author DOI 10.1038/bjc.2016.295↗
  22. Low Stromal Area and High Stromal Microvessel Density Predict Poor Prognosis in Pancreatic Cancer. Last author DOI 10.1097/mpa.0000000000000499↗
  23. Prrx1 isoform switching regulates pancreatic cancer invasion and metastatic colonization. Co-author DOI 10.1101/gad.263327.115↗
  24. [Two Cases of Remnant Pancreatic Cancer Treated Using Remnant Pancreatectomy Combined with Hepatic Arterial Resection]. Last author PMID 28133092↗
  25. [A Case of Early-Onset Rapidly Progressive Cerebral Infarction with Trousseau's Syndrome in a Patient with Pancreatic Cancer Undergoing Surgery]. Last author PMID 28133197↗
  26. Combined vascular resection and reconstruction during hepatobiliary and pancreatic cancer surgery. Co-author DOI 10.1002/bjs.9618↗
  27. Prognostic relevance of apparent diffusion coefficient obtained by diffusion-weighted MRI in pancreatic cancer. Co-author DOI 10.1002/jmri.24939↗
  28. [III. Repeat pancreatectomy for recurrent pancreatic cancer]. Last author PMID 26665417↗
  29. [A Case of R0 Resection of Locally Advanced Pancreatic Cancer Following Chemoradiation Therapy]. Last author PMID 26805371↗
  30. Tips and tricks of surgical technique for pancreatic cancer: portal vein resection and reconstruction (with videos). Last author DOI 10.1002/jhbp.128↗
  31. [Liver, pancreas, biliary tract cancer. III. Pancreatectomy with Vascular Resection for Locally Advanced Pancreatic Cancer]. Last author PMID 25528776↗
  32. Role of adjuvant surgery for patients with initially unresectable pancreatic cancer with a long-term favorable response to non-surgical anti-cancer treatments:… Co-author DOI 10.1007/s00534-013-0616-0↗
  33. Clinical usefulness of repeated pancreatic juice cytology via endoscopic naso-pancreatic drainage tube in patients with pancreatic cancer. Co-author DOI 10.1007/s00535-012-0684-y↗
  34. Akt/mTOR signaling pathway is crucial for gemcitabine resistance induced by Annexin II in pancreatic cancer cells. Last author DOI 10.1016/j.jss.2012.05.065↗
  35. The application of a three-step proteome analysis for identification of new biomarkers of pancreatic cancer. Co-author DOI 10.1155/2011/628787↗

Closest collaborators

The 25 strongest of 61 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Hideyuki Yoshitomi · 26 shared papers, 2011–2021 · strength 1.70
  2. Shigetsugu Takano · 24 shared papers, 2011–2022 · strength 1.60
  3. Masayuki Ohtsuka · 21 shared papers, 2012–2022 · strength 1.46
  4. Katsunori Furukawa · 18 shared papers, 2012–2021 · strength 1.09
  5. Shingo Kagawa · 17 shared papers, 2012–2021 · strength 1.06
  6. Atsushi Kato · 3 shared papers, 2014–2019 · strength 0.28
  7. Hitoe Nishino · 3 shared papers, 2017–2022 · strength 0.28
  8. Mamoru Satoh · 5 shared papers, 2011–2021 · strength 0.27
  9. Fumio Nomura · 5 shared papers, 2011–2021 · strength 0.27
  10. Reiri Shimazaki · 3 shared papers, 2017–2021 · strength 0.25
  11. Kazuyuki Sogawa · 4 shared papers, 2011–2021 · strength 0.24
  12. Atsuhiko Ueda · 3 shared papers, 2016–2019 · strength 0.20
  13. Masayuki Otsuka · 2 shared papers, 2017–2020 · strength 0.17
  14. Ryosuke Okura · 2 shared papers, 2018–2019 · strength 0.16
  15. Takahiro Nishida · 3 shared papers, 2015–2016 · strength 0.15
  16. Taku Higashihara · 2 shared papers, 2017–2018 · strength 0.15
  17. Yoji Miyahara · 2 shared papers, 2015–2021 · strength 0.15
  18. Takanori Konishi · 1 shared paper, 2022 · strength 0.14
  19. Kensuke Suzuki · 2 shared papers, 2017 · strength 0.14
  20. Osamu Yokosuka · 3 shared papers, 2013–2016 · strength 0.13
  21. Rintaro Mikata · 3 shared papers, 2013–2016 · strength 0.13
  22. Makoto Shinoto · 1 shared paper, 2020 · strength 0.11
  23. Shigeru Yamada · 1 shared paper, 2020 · strength 0.11
  24. Masatoshi Oya · 1 shared paper, 2020 · strength 0.11
  25. Kosuke Sasaki · 1 shared paper, 2021 · strength 0.11

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.